Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ GPR17 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5120874
This item is not returnable.
View return policy
Description
Positive test controls include: Mouse spinal cord, Mouse brain, Rat brain. Immunogen sequence: MSKRSWWAGS RKPPREMLKL SGSDSSQSMN GLEVAPPGLI TNFSLATAEQ CGQETPLENM LFASFYLLDF ILALVGNTLA LWLFIRDHKS GTPA.
The G-protein-coupled receptor (GPCR) superfamily is comprised of an estimated 600-1,000 members and is the largest known class of molecular targets with proven therapeutic value. GPR17 is an orphan G protein-coupled receptor involved in orchestration of oligodendrocyte differentiation and myelination in the central nervous system. GPR17 is expressed in brain, kidney, heart and umbilical vein endothelial cells. GPR17 has dual specificity for uracil nucleotides and cysteinyl leukotrienes and signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and cysteinyl leukotrienes following ischemia.
Specifications
GPR17 | |
Polyclonal | |
Unconjugated | |
GPR17 | |
AI853548; DKFZp686M18273; G protein-coupled receptor 17; Gpr17; gpr17 {ECO:0000312; G-protein coupled receptor 17; P2Y-like receptor; R12; RGD:1589785}; UDP/CysLT receptor; Uracil nucleotide/cysteinyl leukotriene receptor; Y12546; Z94155 | |
Rabbit | |
Affinity chromatography | |
RUO | |
2840, 574402, 767613 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
ELISA, Western Blot | |
0.61 mg/mL | |
PBS with 50% glycerol and 0.01% thimerosal; pH 7.3 | |
Q09QM4, Q13304, Q6NS65 | |
GPR17 | |
Recombinant fusion protein containing a sequence corresponding to amino acids 1-94 of human GPR17 (NP_005282.1). | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction